Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
When imipenem is dosed at 1 g q8h for serious infections, it is infused over 40-60 min. Its label states that it is indicated for “lower RTI”, an old-fashioned term from the days when bronchitis and pneumonias were still lumped together, CAP was not differentiated from HAP, and HAP and Continue reading Why Did PK/PD Modeling Fail Doripenem in VAP?
Treating CMV was never easy making prophylaxis the preferred approach for HSCT patients. Since the late 80ies, trials using hyperimmune globulin have come up with mixed results. While treatment was usually safe, efficacy was a lot much harder to prove. More specific monoclonal ab preparations directed against immunodominant surface glycoproteins did not Continue reading CMV Hyperimmune Globulin Data Inconclusive but New Drug Shows Promise